THC

This month’s webinar discussed studies conducted on cannabis and psychedelics for various conditions including anxiety and autism spectrum disorder.

Here, we discuss the importance of calibration metrics and how to measure calibration quality.

This review highlights an in-silico assessment of the binding interactions of pro-drug moiety analogs and an importance in identifying potential issues that would need further testing to ensure safety for consumers such as the hERG values which are pertinent in the pharmaceutical fields in whether or not drugs can be safe to use.

Here, Scott Mazza, Founder of Vitality CBD, compares the effects of the cannabis compounds CBD and THC for use with various conditions.

This month’s Healer webinar discussed several studies on cannabis and symptoms of dementia and cognitive decline.

This article discusses the early experiments and studies on the effects of two cannabinoids on anxiety.

As markets mature, manufacturing terpene blends have become a new art form and a differentiating factor for potential therapeutic applications. Here, we dive deeper into the insights of terpene formulation considerations.

In this blog installment, we take a deep dive into research on how cannabis affects neurodegenerative disorders such as Alzheimer’s disease, multiple sclerosis, and Parkinson’s disease.

This blog installment looks at the use of cannabis for pets. Topics covered include the history of cannabis use in veterinary medicine, current laws on cannabis for pets, market size and segment, reported experiences from both pet owners and veterinarians, and pet toxicology.

Brandy Young, PhD, the CEO and Founder of Certainty Analytical Labs in New York, discussed her work in compliance testing for cannabis products at EAS 2023.

Whether someone is struggling with acute or chronic pain, cannabis can be a powerful tool as an alternative or adjunct treatment.

One recently published study suggests that a cannabis sublingual spray may be beneficial in the treatment of type 2 diabetes.

One of the recurring challenges in the medical cannabis space is the difficulty in conducting research because of the plant’s Schedule I status. Although there are some researchers diving in with special licenses to conduct clinical studies, there are others that are looking at real-world users to supply data. For instance, Dr. Daniel J. Kruger is a Research Investigator with the Population Study Center at the University of Michigan and Principal Investigator on a study being conducted with the Releaf app. Here, Dr. Kruger shares his interest and background in these types of surveys and his plans for the current study with Releaf on chronic pain.